The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

February 12, 2024

Study Completion Date

August 30, 2026

Conditions
HIV Infections
Interventions
DRUG

Standard of Care (SOC) Oral ART

SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)

DRUG

Oral RPV

RPV 25 mg tablets

DRUG

Oral CAB

CAB 30 mg tablets

DRUG

RPV-LA Loading Dose

900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle

DRUG

CAB-LA Loading Dose

600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

DRUG

RPV-LA Maintenance Dose

600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle

DRUG

CAB-LA Maintenance Dose

400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle

Trial Locations (33)

10010

Weill Cornell Chelsea CRS, New York

10065

Weill Cornell Uptown CRS, New York

10461

Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx

11794

SUNY Stony Brook NICHD CRS, Stony Brook

15213

University of Pittsburgh CRS, Pittsburgh

19104

Penn Therapeutics, CRS, Philadelphia

21205

Johns Hopkins University CRS, Baltimore

27401

Greensboro CRS, Greensboro

27599

Chapel Hill CRS, Chapel Hill

32209

Univ. of Florida Jacksonville NICHD CRS, Jacksonville

35294

Alabama CRS, Birmingham

37204

Vanderbilt Therapeutics (VT) CRS, Nashville

43210

Ohio State University CRS, Columbus

44106

Case Clinical Research Site, Cleveland

45219

Cincinnati Clinical Research Site, Cincinnati

60611

Northwestern University CRS, Chicago

60612

Rush University CRS, Chicago

77030

Houston AIDS Research Team CRS, Houston

80045

University of Colorado Hospital CRS, Aurora

90035

UCLA CARE Center CRS, Los Angeles

90502

Harbor-UCLA CRS, Torrance

92103

UCSD Antiviral Research Center CRS, San Diego

94110

Ucsf Hiv/Aids Crs, San Francisco

90033-1079

University of Southern California CRS, Los Angeles

30308-2012

The Ponce de Leon Center CRS, Atlanta

02114

Massachusetts General Hospital CRS (MGH CRS), Boston

02115

Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston

63110-1010

Washington University Therapeutics (WT) CRS, St Louis

07103

New Jersey Medical School Clinical Research Center CRS, Newark

10032-3732

Columbia P&S CRS, New York

02906

The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence

98104-9929

University of Washington AIDS CRS, Seattle

00935

Puerto Rico AIDS Clinical Trials Unit CRS, San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03635788 - The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE | Biotech Hunter | Biotech Hunter